Eosinophilic Esophagitis Patients Are Not at Increased Risk of Severe COVID-19: A Report From a Global Registry

Noam Zevit*, Mirna Chehade, John Leung, Luba Marderfeld, Evan S. Dellon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The impact of coronavirus disease 2019 (COVID-19) on eosinophilic esophagitis (EoE) and eosinophilic gastrointestinal diseases (EGIDs) is unknown. Objective: We aimed to characterize patients with EoE and EGIDs who had COVID-19, assess severity of COVID-19 in the EoE/EGID population, and evaluate for COVID-19-induced EoE/EGID flares. Methods: We established an online global registry collecting physician entered, deidentified data related to patient demographics, EoE/EGID disease features, comorbidities, and treatments, COVID-19 source of exposure, symptoms, illness severity, hospitalizations, and deaths. Results: Ninety-four cases were reported between March 2020 and April 2021 (median age, 21 years; range, 1.5-53 years; 73% male). Most had atopy (73%), and 80% had isolated EoE. Before COVID-19, the EoE/EGID activity was reported as clinical remission in 51 (54%) and moderate in 20 (21%). EoE/EGID treatments at the time of COVID-19 included proton pump inhibitors 49 (52%), swallowed/topical steroids 48 (51%), and dietary elimination 34 (36%). COVID-19 symptoms included cough (56%), fever (49%), anosmia (21%), and ageusia (22%). Most patients with COVID-19 had a mild course (70%), with 15% asymptomatic, 12% moderate, and 2% severe. Three patients were hospitalized, and no intensive care unit admissions or deaths were reported. Mean time from first symptoms to resolution in symptomatic patients was 10 days (range, 1-90 days). A single EGID flare was reported during COVID-19. Conclusions: In a global EoE/EGID registry, relatively few COVID-19 cases have been reported. COVID-19 severity was comparable to the general population. Based on this registry, it does not appear that patients with EoE are at increased risk for severe COVID-19 infection or that COVID-19 leads to EGID flares.

Original languageEnglish
Pages (from-to)143-149.e9
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume10
Issue number1
DOIs
StatePublished - Jan 2022

Funding

FundersFunder number
American Partnership for Eosinophilic Disorders/American Academy of Allergy
Shire/Takeda
National Institutes of HealthR01-AI140133, R01-ES031940
National Institute of Allergy and Infectious DiseasesU54AI117804
Bristol-Myers Squibb
AstraZeneca
Sanofi

    Keywords

    • COVID-19
    • Corona virus
    • EGID
    • Eosinophilic GI disease
    • Eosinophilic oesophagitis
    • Epidemiology
    • Outcome
    • Risk factor

    Fingerprint

    Dive into the research topics of 'Eosinophilic Esophagitis Patients Are Not at Increased Risk of Severe COVID-19: A Report From a Global Registry'. Together they form a unique fingerprint.

    Cite this